AAAAAA

   
Results: 1-7 |
Results: 7
Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS
Authors: Rudick, RA Cutter, G Baier, M Fisher, E Dougherty, D Weinstock-Guttman, B Mass, MK Miller, D Simonian, NA
Citation: Ra. Rudick et al., Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS, NEUROLOGY, 56(10), 2001, pp. 1324-1330
Use of the Multiple Sclerosis Functional Composite as an outcome measure in a phase 3 clinical trial
Authors: Cohen, JA Cutter, GR Fischer, JS Goodman, AD Heidenreich, FR Jak, AJ Kniker, JE Kooijmans, MF Lull, JM Sandrock, AW Simon, JH Simonian, NA Whitaker, JN
Citation: Ja. Cohen et al., Use of the Multiple Sclerosis Functional Composite as an outcome measure in a phase 3 clinical trial, ARCH NEUROL, 58(6), 2001, pp. 961-967
Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients
Authors: Fisher, E Rudick, RA Cutter, G Baier, M Miller, D Weinstock-Guttman, B Mass, MK Dougherty, DS Simonian, NA
Citation: E. Fisher et al., Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients, MULT SCLER, 6(6), 2000, pp. 373-377
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.
Authors: Jacobs, LD Beck, RW Simon, JH Kinkel, RP Brownscheidle, CM Murray, TJ Simonian, NA Slasor, PJ Sandrock, AW
Citation: Ld. Jacobs et al., Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis., N ENG J MED, 343(13), 2000, pp. 898-904
Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration
Authors: Rogge, MC Simonian, NA Jones, WE
Citation: Mc. Rogge et al., Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration, EUR J NEUR, 6(3), 1999, pp. 375-375
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (R) (IFN beta-1a) for relapsing multiple sclerosis
Authors: Rudick, RA Cookfair, DL Simonian, NA Ransohoff, RM Richert, JR Jacobs, LD Herndon, RM Salazar, AM Fischer, JS Granger, CV Goodkin, DE Simon, JH Bartoszak, DM Bourdette, DN Braiman, J Brownscheidle, CM Coats, ME Cohan, SL Dougherty, DS Kinkel, RP Mass, MK Munchsauer, FE O'Reilly, K Priore, RL Pullicino, PM Scherokman, BJ Wende, K Weinstock-Guttman, B Whitham, RH
Citation: Ra. Rudick et al., Cerebrospinal fluid abnormalities in a phase III trial of Avonex (R) (IFN beta-1a) for relapsing multiple sclerosis, J NEUROIMM, 93(1-2), 1999, pp. 8-14
"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis
Authors: Simonian, NA McAllister, A Lull, J
Citation: Na. Simonian et al., "Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis, J NE NE PSY, 66(4), 1999, pp. 553-553
Risultati: 1-7 |